Necrostatin-1

别名: Nec-1

目录号：S8037 Purity: 99.97%

Necrostatin-1 (Nec-1)是一种特异性RIP1 (RIPK1)抑制剂，抑制TNF-α诱导的细胞坏死，在293T细胞中EC50为490 nM。Necrostatin-1也可抑制 IDO、细胞自噬和凋亡。

Necrostatin-1 Chemical Structure

CAS: 4311-88-0

规格	价格	库存
10mM (1mL in DMSO)	1054.09	现货
10mg	814.14	现货
100mg	2224.79	现货
1g	7944.3	现货
更大包装有超大折扣
400-668-6834 info@selleck.cn

产品质控

批次：纯度： 99.97%

99.97

Necrostatin-1相关产品

相关靶点	RIP1 kinase RIP2 kinase RIP3 kinase RIP 1 Kinase	点击展开
相关产品	GSK'872 Necrostatin 2 racemate (Nec-1s) Mito-TEMPO RIPA-56 GSK2982772 GSK'963 GSK583 GSK2983559 (compound 3) Resibufogenin GSK'547 ICCB-19 hydrochloride HS-1371 GSK481	点击展开
相关化合物库	自噬化合物库凋亡分子化合物库铁死亡化合物库细胞焦亡化合物库线粒体靶向化合物库	点击展开

细胞实验数据示例

细胞系	实验类型	给药浓度	孵育时间	活性描述	文献信息
L929	Growth Inhibition Assay	2/5 μg/ml	24 h	reverses the cell growth inhibition and cell death induced by TNFα alone as well as TNFα + zVAD	23941769
L929	Function Assay	2 μg/ml	24 h	promots caspase-6 (p20) activity and procaspase-6 cleavage	23941769
L929	Function Assay	5 μg/ml	24 h	blocks zVAD induced necroptosis and autophagy	23941769
C6	Cell Viability Assay	1 mmol/L	3 h	attenuates Shikonin induced glioma cell death	23840441
U87	Cell Viability Assay	1 mmol/L	3 h	attenuates Shikonin induced glioma cell death	23840441
C6	Cytotoxicity Assay	1 mmol/L	3 h	blocks shikonin induced necrosis	23840441
U87	Cytotoxicity Assay	1 mmol/L	3 h	blocks shikonin induced necrosis	23840441
C6	Function Assay	1 mmol/L	1.5-3 h	suppresses the expression of RIP-1 caused by shikonin	23840441
U87	Function Assay	1 mmol/L	1.5-3 h	suppresses the expression of RIP-1 caused by shikonin	23840441
TE671	Cell Viability Assay	40 μg/ml	24 h	rescues GX15-070-induced loss of cell viability	23744296
RMS13	Cell Viability Assay	40 μg/ml	24 h	rescues GX15-070-induced loss of cell viability	23744296
MEFs	Cytotoxicity Assay	2/6/20 μM	18 h	inhibits TNFα-induced cell death in RelA KO MEFs	23727581
MEFs	Function Assay	20 μM	1/2/4 h	suppresses TNFα-induced RIPK1 phosphorylation	23727581
ΔN-Karpas 299	Cytotoxicity Assay	20 μM	16 h	inhibits CD30-induced cell death	23545938
MM.1S	Cytotoxicity Assay	90 µM	1 h	blocks BAY 11-7082 induced rapid cell swelling	23527154
KMS-12-BM	Cytotoxicity Assay	90 µM	1 h	blocks BAY 11-7082 induced rapid cell swelling	23527154
HT-22	Cell Viability Assay	10 μM	12 h	protects against glutamate-induced cell death	23307752
HT-22	Function Assay	25 μM	0–30 min	inhibits ERK Activation induced by glutamate	23307752
NIH3T3	Function Assay	10/50 μM	1/3 h	ameliorates TNFα-driven complex formation	23261677
SH-EP	Apoptosis Assay	10 μM	72 h	inhibits IAP inhibitor- and Lexatumumab-induced apoptosis	22890322
HL60	Apoptosis Assay	60 μM	12 h	enhances shikonin-induced apoptosis	22837689
HL60/Adr	Apoptosis Assay	60 μM	12 h	enhances shikonin-induced apoptosis	22837689
K562	Apoptosis Assay	60 μM	12 h	enhances shikonin-induced apoptosis	22837689
K562/Adr	Apoptosis Assay	60 μM	12 h	enhances shikonin-induced apoptosis	22837689
HL60	Function Assay	60 μM	12 h	augments the caspase-3 activity	22837689
HL60/Adr	Function Assay	60 μM	12 h	augments the caspase-3 activity	22837689
K562	Function Assay	60 μM	12 h	augments the caspase-3 activity	22837689
K562/Adr	Function Assay	60 μM	12 h	augments the caspase-3 activity	22837689
HL60	Function Assay	60 μM	12 h	increases the activity of caspases, caspase 8 and 9	22837689
HL60/Adr	Function Assay	60 μM	12 h	increases the activity of caspases, caspase 8 and 9	22837689
K562	Function Assay	60 μM	12 h	increases the activity of caspases, caspase 8 and 9	22837689
K562/Adr	Function Assay	60 μM	12 h	increases the activity of caspases, caspase 8 and 9	22837689
L929sA	Apoptosis Assay	10 μM	1 h	inhibits the apoptotic response to TNF	22362767
L929sA	Apoptosis Assay	10 μM	1 h	rescues cells expressing RIPK1ΔID from TNF-induced apoptosis	22362767
L929sA	Apoptosis Assay	10 μM	1 h	abrogates the interaction of caspase-8 with FADD	22362767
TPC-1	Cell Viability Assay	100 μM	24 h	increases cellular survival	22136818
8505c	Cell Viability Assay	100 μM	24 h	increases cellular survival	22136818
SW13	Cell Viability Assay	100 μM	24 h	increases cellular survival	22136818
Jurkat	Cytotoxicity Assay	50/ 100/200 μm	1/3 h	reduces Naegleria fowleri-induced cytotoxicity	21535020
Jurkat	Function Assay	200 μm	30 min	reduces Naegleria fowleri-induced reactive oxygen species (ROS) generation	21535020
HT-22	Cytotoxicity Assay	10 μM	12 h	protects against cell death induced by 5 mmol/L glutamate	17760869
L929	Function Assay	2/5 μg/ml	24 h	reversed the autophagy induced by TNFα alone as well as TNFα + zVAD	23941769
NRK-52E	Cell Viability Assay	20 μM	24 h	inhibits increased Drp1 protein expression after TNF-α Stimulation and ATP Depletion	24351845
NRK-52E	Cell Viability Assay	20 μM	24 h	increases cell viability after TNF-α Stimulation and ATP Depletion	24351845
NRK-52E	Cell Viability Assay	20 μM	24 h	protects cells from cell death caused by ischemia injury	24351845
AGS	Cell Viability Assay	60 μm	1 h	prevents shikonin-induced cell death	24463199
L-540	Cell Viability Assay	60 μm	1 h	reduces the Givinostat/Sorafenib-induced cell death	24561519
L-540	Function Assay	60 μm	1 h	prevents the mitochondrial membrane depolarization	24561519
L-540	Function Assay	60 μm	1 h	prevents the generation of ROS	24561519
SK-Hep1	Function Assay	60 μM	18 h	blocks β-lapachone-mediated PAR accumulation and AIF translocation to the cytosol	24832602
SK-Hep1	Function Assay	60 μM	18 h	inhibits β-Lapachone-induced leakage of HMGB-1	24832602
SK-Hep1	Function Assay	60 μM	18 h	blocks β-lapachone-induced morphological change, cell death and PI uptake	24832602
Huh7	Cell Viability Assay	50 µM	24/48 h	prevents cell death of rAdHCV co-infected Huh7 cells	24973240
L929	Cell Viability Assay	30 μM	1 h	inhibits TNF-α-induced cleavage of Topo I	25095742
L929	Cell Viability Assay	30 μM	1 h	inhibits TNF-α-induced loss of cell viability	25095742
L929-A	Function Assay	50 μM	12 h	inhibits the TNFα-induced loss of mitochondrial membrane permeability	25398540
L929	Function Assay	50 μM	12 h	inhibits TNFα-induced Bid cleavage	25398540
L929-N	Function Assay	50 μM	12 h	blocks the cleavage of Caspase-3 and PARP	25398540
L929-A	Function Assay	50 μM	12 h	blocks the cleavage of Caspase-3 and PARP	25398540
L929-N	Cell Viability Assay	50 μM	24 h	blocks TNFα-induced cell death	25398540
L929-A	Cell Viability Assay	50 μM	24 h	blocks TNFα-induced cell death	25398540
KMS-12-PE	Cell Viability Assay	60 μM	5 h	inhibits SHK-induced cell death	25530098
SGC-7901	Cell Viability Assay	30 μM	1 h	suppresses oxaliplatin-mediated cell death	25767076
BxPC-3	Function Assay	20 μM	24 h	decreases the early necrotic cells	26000607
MiaPaCa-2	Function Assay	20 μM	24 h	decreases the early necrotic cells	26000607
NCI-H28	Cell Viability Assay	10 μM	24 h	prevents DAPE-induced reduction of NCI-H28 cell viability	26004138
BMDM	Function Assay	10 μM	30 min	protects cells from TAKI-induced LDH release	26381601
MEFs	Cell Viability Assay	10 μM	48 h	inhibits zVAD-promoted death of CNOT3-depleted MEFs	26437789
A549	Cell Viability Assay	50 μM	24 h	inhibits MMS-induced cell death	26472723
Jurkat T	Necroptosis assay	30 uM	24 hrs	Inhibition of necroptosis in TNF-alpha-induced human Jurkat T cells assessed as cell viability at 30 uM after 24 hrs	18467094
L929	Necroptosis assay	30 uM	24 hrs	Inhibition of necroptosis in zVAD-induced mouse L929 cells assessed as cell viability at 30 uM after 24 hrs	18467094
L929	Necroptosis assay	30 uM	24 hrs	Inhibition of necroptosis in TNF-alpha-induced mouse L929 cells assessed as cell viability at 30 uM after 24 hrs	18467094
Jurkat	Cytoprotective assay	30 uM	1 hr	Cytoprotective activity against FasL-induced necroptosis in human Jurkat cells assessed as increase in cell viability at 30 uM incubated for 1 hr followed by FasL stimulation measured after 20 hrs by Alamar blue assay	29541357
Jurkat	Cytoprotective assay	30 uM	1 hr	Cytoprotective activity against CHX-induced necroptosis in human Jurkat cells assessed as increase in cell viability at 30 uM incubated for 1 hr followed by CHX stimulation by Alamar blue assay	29541357
Jurkat	Cytoprotective assay	30 uM	1 hr	Cytoprotective activity against Z-VAD-induced necroptosis in human Jurkat cells assessed as increase in cell viability at 30 uM incubated for 1 hr followed by Z-VAD stimulation by Alamar blue assay	29541357
Jurkat	Cytoprotective assay	30 uM	1 hr	Cytoprotective activity against FasL-induced necroptosis in human Jurkat cells assessed as increase in cell viability at 30 uM incubated for 1 hr followed by FasL stimulation measured after 20 hrs by phase contrast microscopy	29541357
Jurkat	Cytoprotective assay	30 uM	1 hr	Cytoprotective activity against CHX-induced necroptosis in human Jurkat cells assessed as increase in cell viability at 30 uM incubated for 1 hr followed by CHX stimulation by phase contrast microscopy	29541357
Jurkat	Cytoprotective assay	30 uM	1 hr	Cytoprotective activity against Z-VAD-induced necroptosis in human Jurkat cells assessed as increase in cell viability at 30 uM incubated for 1 hr followed by Z-VAD stimulation by phase contrast microscopy	29541357
OHC	Function Assay	300 μM		increases the number of apoptotic OHCs without altering the levels of CC8 after noise exposure	24874734
OHC	Function Assay	300 μM		diminishes noise-induced AMPK activation	24874734
OHC	Function Assay	300 μM		results in a reduction of noise-induced RIP1 and RIP3 immunofluorescence	24874734
OHC	Function Assay	300 μM		decreases noise-induced swollen nuclei	24874734
OHC	Function Assay	300 μM		increases noise-induced condensed nuclei	24874734
Sf9	Function assay		30 mins	Inhibition of recombinant human GST-fused RIPK1 (1 to 497 residues) expressed in baculovirus infected insect Sf9 cells in presence of 32P-gamma-ATP after 30 mins by autoradiogram-based Western blot method, IC50 = 0.182 μM.	28280261
3T3	Cell death assay		24 hrs	Inhibition of death receptor signaling mediated necrotic cell death in mouse 3T3 cells assessed as cell viability after 24 hrs by ATP based viability assay in presence of TNFalpha and zVAD.fmk	16408008
3T3	Cell death assay		24 hrs	Inhibition of death receptor signaling mediated necrotic cell death in mouse 3T3 cells assessed as cell viability after 24 hrs by ATP based viability assay in presence of FasL and zVAD.fmk	16408008
MEF	Cell death assay		16 hrs	Inhibition of death receptor signaling mediated necrotic cell death in SV40 transformed mouse MEF cells assessed as cell viability after 16 hrs by ATP based viability assay in presence of TNFalpha, CHX and zVAD.fmk	16408008
L929	Cell death assay		24 hrs	Inhibition of death receptor signaling mediated necrotic cell death in mouse L929 cells assessed as cell viability after 24 hrs by ATP based viability assay in presence of TNFalpha	16408008
U937	Cell death assay		48 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in human U937 cells assessed as cell viability after 48 hrs by ATP based viability assay in presence of TNFalpha and zVAD-fmk	16408008
3T3	Cell death assay		24 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in mouse 3T3 cells assessed as cell viability after 24 hrs by ATP based viability assay in presence of TNFalpha and zVAD-fmk	16408008
Jurkat	Cell death assay		24 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD assessed as decreased levels of PE-conjugated LC3-II (autophagy marker) after 24 hrs by Western blot method in presence of TNFalpha	16408008
L929	Cell death assay		24 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in mouse L929 cells assessed as decreased levels of PE-conjugated autophagy marker LC3-II after 24 hrs by Western blot method in presence of TNFalpha	16408008
3T3	Cell death assay		24 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in mouse 3T3 cells assessed as decreased levels of PE-conjugated autophagy marker LC3-II after 24 hrs by Western blot method in presence of TNFalpha and zVAD-fmk	16408008
3T3	Cell death assay		24 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in mouse 3T3 cells assessed as decreased levels of PE-conjugated autophagy marker LC3-II after 24 hrs by Western blot method in presence of FasL and zVAD-fmk	16408008
3T3	Cell death assay		24 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in mouse 3T3 cells assessed as decreased levels of PE-conjugated autophagy marker LC3-II after 24 hrs by Western blot method in presence of rapamycin	16408008
Jurkat	Cell death assay		48 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing FKBP12-based dimerization domain assessed as cell viability after 48 hrs by FACS in presence of AP1510, zVAD-fmk	16408008
Jurkat	Cell death assay		48 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing RIP kinase assessed as cell viability after 48 hrs by FACS in presence of AP1510, zVAD-fmk	16408008
Jurkat	Cell death assay		48 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing RIP K45M mutant assessed as cell viability after 48 hrs by FACS in presence of AP1510, zVAD-fmk	16408008
Jurkat	Cell death assay		48 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing RIP kinase domain assessed as cell viability after 48 hrs by FACS in presence of AP1510, zVAD-fmk	16408008
Jurkat	Cell death assay		48 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing FKBP12-based dimerization domain assessed as cell viability after 48 hrs by FACS in presence of AP1510	16408008
Jurkat	Cell death assay		48 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing RIP kinase assessed as cell viability after 48 hrs by FACS in presence of AP1510	16408008
Jurkat	Cell death assay		48 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing RIP K45M mutant assessed as cell viability after 48 hrs by FACS in presence of AP1510	16408008
Jurkat	Cell death assay		48 hrs	Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cells deficient in FADD and expressing RIP kinase domain assessed as cell viability after 48 hrs by FACS in presence of AP1510	16408008
Jurkat T	Necroptosis assay			Inhibition of TNF-alpha-induced necroptosis in FADD-deficient human Jurkat T cells, EC50 = 0.05 μM.	18467094
Jurkat	Function assay			Inhibition of endogenous RIP1 autophosphorylation in human Jurkat cells, EC50 = 0.182 μM.	18408713
Jurkat T	Necroptosis assay			Effective concentration required for inhibition of necroptosis in FADD deficient Jurkat T cells treated with TNF-alpha, EC50 = 0.49 μM.	16153840
Jurkat	Necroptosis assay			Inhibition of cellular necroptosis in TNFalpha treated FADD deficient human Jurkat cells, EC50 = 0.49 μM.	18408713
IEC18	Cell death assay			Inhibition of death receptor signaling mediated necrotic cell death in rat IEC18 cells assessed as cell viability in presence of TNFalpha and zVAD.fmk	16408008
HL60	Cell death assay			Inhibition of death receptor signaling mediated necrotic cell death in human HL60 cells assessed as cell viability in presence of TNFalpha and zVAD.fmk	16408008
Jurkat	Necrosis assay			Inhibition of necrosis in human Jurkat cells assessed as nuclear condensation by bright field microscopy in presence of FasL, CHX and zVAD-fmk	16408008
Jurkat	Necrosis assay			Inhibition of necrosis in human Jurkat cells assessed as organelle swelling by bright field microscopy in presence of FasL, CHX and zVAD-fmk	16408008
Jurkat	Necrosis assay			Inhibition of necrosis in human Jurkat cells assessed as early loss of plasma membrane integrity by bright field microscopy in presence of FasL, CHX and zVAD-fmk	16408008
Jurkat	Necrosis assay			Inhibition of necrosis in human Jurkat cells assessed as appearance of translucent cytosol in presence of FasL, CHX and zVAD-fmk	16408008
Jurkat	Necrosis assay			Inhibition of necrosis in human Jurkat cells deficient in FADD assessed as inhibition of nuclear condensation by bright field microscopy in presence of TNFalpha	16408008
Jurkat	Necrosis assay			Inhibition of necrosis in human Jurkat cells deficient in FADD assessed as inhibition of organelle swelling by bright field microscopy in presence of TNFalpha	16408008
Jurkat	Necrosis assay			Inhibition of necrosis in human Jurkat cells deficient in FADD assessed as inhibition of early loss of plasma membrane integrity by bright field microscopy in presence of TNFalpha	16408008
Jurkat	Necrosis assay			Inhibition of necrosis in human Jurkat cells deficient in FADD assessed as inhibition of appearance of translucent cytosol in presence of TNFalpha	16408008
Sf9	Function assay			Inhibition of human RIP1 K45M mutant autophosphorylation expressed in Sf9 cells	18408713
点击查看更多细胞系数据

生物活性

产品描述

Necrostatin-1 (Nec-1)是一种特异性RIP1 (RIPK1)抑制剂，抑制TNF-α诱导的细胞坏死，在293T细胞中EC50为490 nM。Necrostatin-1也可抑制 IDO、细胞自噬和凋亡。

特性

Necrostatin-1是抑制细胞坏死的有力工具。

靶点

IDO ^[1]	RIP1 ^[1] (293T cells)
	490 nM(EC50)

体外研究(In Vitro)
体外研究活性	Necrostatin-1 (1-100 μM) 抑制过表达和内源性的RIP1发生自磷酸化。RIP1是初级细胞靶点，负责Necrostatin-1的抗细胞坏死活性。^[1] Necrostatin-1有效抑制多种类型细胞触发的坏死性细胞死亡。Necrostatin-1作为细胞坏死的小分子抑制剂, 作用于jurkat细胞，抑制RIP激酶的诱导细胞坏死，抑制TNF-α诱导的细胞坏死，EC50为490 nM。^[2]
激酶实验	RIP1 激酶检测
激酶实验	RIP1 的磷酸化需要其激酶活性。FLAG标记的野生型(WT)或RIP1(K45M) 突变体失活激酶的表达结构转染到293T细胞中，在有[γ-³²P]ATP存在时，RIP1激酶实验在30°C下进行30分钟。样品进行SDS-PAGE，通过放射自显影可观察到RIP1带。对放射性带的相对强度进行量化，并显示比率。在激酶反应的同时，珠样本使用anti-RIP1抗体进行Western Blot分析，确保与激酶反应中等量的蛋白。
细胞实验	细胞系	Jurkat, BALB/c 3T3, SV40-转化的MEF, L929
	浓度	0.01-100 μM
	孵育时间	--
	方法	细胞接种在96孔板中（白色板进行发光检测;黑色板进行荧光检测;空白板进行MTT实验）贴壁细胞按每孔5000-10000个细胞的密度接种，悬浮细胞按每孔20,000-50,000个细胞的密度接种，孔中含100 μl合适的无酚红培养基。温育后，使用如下方法之一测定细胞存活率。ATP 实验中，使用购买的发光试剂盒，并使用Wallac Victor II酶标仪分析发光值。Sytox实验中,细胞与 1 μM Sytox Green试剂在37°C下温育30分钟,然后进行荧光读数。随后，增加5 μl 20% Triton X-100溶液到每孔中，产生最大溶解，细胞37°C下温育1小时，然后进行二次读数。Triton处理前和后，计算值的比率。MTT实验，使用CellTiter 96 AQueous 非放射性细胞增殖检测试剂盒。PI排除实验中, 加入2 μg/ml PI 到培养基中，立即使用FACSCalibur分析样品。PI-膜联蛋白V 实验中，使用ApoAlert Annexin V-EGFP 凋亡试剂盒。进行DioC6染色, 细胞与40 nM DiOC₆ 在37°C下温育30分钟, 洗涤一次，使用FACSCalibur分析。ROS分析中, 细胞与5 μM Dihydroethidium在37°C下温育30分钟, 洗涤一次，使用FACSCalibur分析。
实验图片	检测方法	检测指标	实验图片	PMID
实验图片	Immunofluorescence	RIP1 / RIP3		30462730

参考文献
[1] Degterev A, et al. Nat Chem Biol, 2008, 4(5), 313-321. [2] Degterev A, et al. Nat Chem Biol, 2005, 1(2), 112-119. [3] Liang S, et al. Front Pharmacol. 2018 Nov 27;9:1378.

参考文献

化学信息&溶解度

分子量	259.33	分子式	C₁₃H₁₃N₃OS
CAS号	4311-88-0	SDF	Download Necrostatin-1 SDF
Smiles	CN1C(=O)C(NC1=S)CC2=CNC3=CC=CC=C32
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1年-80°C溶于溶剂
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1个月-20°C溶于溶剂

体外溶解度
批次：

DMSO : 57 mg/mL ( (219.79 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

DMSO : 52 mg/mL ( (200.51 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

DMSO : 51 mg/mL ( (196.66 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩尔浓度计算器

体内溶解度
批次：

现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂

动物体内配方计算器

实验计算

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):